Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: Relationship to endothelial dysfunction and laser treatment

Investigative Ophthalmology and Visual Science

Volumn 41, Issue 8, 2000, Pages 2115-2119

  Lip, Peck Lin ^a,b   Belgore, Funmi ^a   Blann, Andrew D ^a   Hope Ross, Monique W ^b   Gibson, Jonathan M ^b   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; ENDOTHELIUM LESION; FEMALE; HUMAN; LASER COAGULATION; LASER SURGERY; MALE; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RELAPSE; RETINA BLOOD VESSEL OCCLUSION; RETINA NEOVASCULARIZATION;

DIABETES COMPLICATIONS; DIABETIC RETINOPATHY; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LASER COAGULATION; LYMPHOKINES; MALE; MIDDLE AGED; PILOT PROJECTS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RETINAL NEOVASCULARIZATION; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS; VON WILLEBRAND FACTOR;

EID: 0033939404     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Aiello L, Northrup J, Keyt B, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995; 113:1538-1544.
2. Murata T, Ishibashi T, Khalil A, et al. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res. 1995;27:48-52.
3. Senger DR, Water LVD, Brown LF, Nagy JA, Yeo KT, Berse B. Vascular permeability factor (VPF, VEGF) in tumour biology. Cancer Metastasis Rev. 1993;12:303-324.
4. Yang Q, Zwijsen A, Siegers H, et al. Purification and characterization of VEGF/VPF secreted by human retinal pigment epithelial cells. Endotbelium. 1994;2:73-85.
5. Aiello LP, Avery RL, Arigg PG, et al. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
6. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-66.
7. Takagi H, King GL, Aiello LP. Identification and characteristic of vascular endothelial growth factor receptor (Fit) in bovine retinal pericytes. Diabetes. 1996;45:1016-1023.
8. Kendall RL. Wang G. Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996;226:324-328.
9. Lip GYH, Blann AD. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res. 1997;34:255-265.
10. Klein R, Klein BEK, Magli YL, et al. An alternative method of grading diabetic retinopathy. Ophthalmology. 1986;93:1183-1187.
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.
12. Heier JS, Morley MG. Venous obstructive disease of the retina. In: Yanoff M, Duker JS, eds. Ophthalmology. London: Mosby International; 1999; Section 8, Chapter 18:1-8.
13. Short PE, Williams CE, Picken AM, Hill FGH. Factor VIII related antigen: an improved enzyme immunoassay. Med Lab Sci. 1982; 39:351-355.
14. Eckerbom S, Bergquist Y, Jeppsson J. Improved method for analysis of glycated haemoglobulin by ion exchange chromatography. Ann Clin Biochem. 1994;31:355-360.
15. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol. 1996;80:241-245.
16. 1a-c. Ann Intern Med. 1978;88:311-316.
17. Murray PI, Young DW, Aggarwal RJ, Blann AD. Von Willebrand factor, endothelial damage and ocular disease. Ocular Immunol Inflamm. 1993;1:315-322.
18. Shinoda K, Ishida S, Kawashima S, et al. Comparison of levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus. Br J Ophthalmol. 1999;83:834-837.
19. Kozawa T, Sone H, Okuda Y, et al. Vascular endothelial growth factor levels in the aqueous and serum in diabetic retinopathy with or without neovascular glaucoma. Nippon Ganka Gakkai Zasshi. 1998;102:731-738 (in Japanese).
20. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PEC. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci. 1998;94:395-404.